Icu Medical — Q2 2025 Earnings Presentation

4 slides from Icu Medical's earnings presentation, Aug 7, 2025

Slide 1: ICU Medical, Inc Q2 2025 Conference Call Presentation
ICU Medical, Inc Q2 2025 Conference Call Presentation August 7, 2025 1
Slide 2: Disclosures
Disclosures > Any statement concerning Management’s expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a rep
Slide 3: 2024-2025 Adjusted Revenue
2024-2025 Adjusted Revenue In $Millions Tracheostomy 2024 2024 2024 2024 2024 2025 2025 Q1 Q2 Q3 Q4 Total Q1 Q2 Vascular Access Consumables 244 262 265 268 1,039 266 273 YoY Growth 3% 10% 9% 6% 7% 9% 4% 1 YoY Organic Growth 3% 11% 9% 6% 7% 10% 3% Syringe Oncology Systems 157 164 160 172 652 166 168
Slide 4: 2025 Guidance and Modeling Assumptions
2025 Guidance and Modeling Assumptions In $ Millions, except per share amounts Q1 Guidance Excluding JV Transaction JV Transaction Impact Post JV Transaction Q2 Guidance Update (reflects May 1, 2025 closing) Adj EBITDA $395m to $425m ($15m) to ($20m) $380m to $405m $380m to $390m Adj EPS $6.55 to $7